Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Apixaban

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    88 result(s) found for: Apixaban. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2019-002353-29 Sponsor Protocol Number: HUB-NEF-HEMOCIONA.EC Start Date*: 2019-11-12
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL
    Full Title: PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF APIXABAN IN PATIENTS IN HEMODAFILTRATION
    Medical condition: Chronic kidney disease, non-valvular atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000758-28 Sponsor Protocol Number: 19767 Start Date*: 2022-11-23
    Sponsor Name:Bayer AG
    Full Title: A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibito...
    Medical condition: Prevention of stroke or systemic embolism in atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10049165 Cerebrovascular accident prophylaxis PT
    21.1 10042613 - Surgical and medical procedures 10049910 Thromboembolism prophylaxis LLT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) ES (Trial now transitioned) SE (Trial now transitioned) HU (Trial now transitioned) NO (Trial now transitioned) SK (Trial now transitioned) LT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002365-35 Sponsor Protocol Number: 19765 Start Date*: 2020-01-24
    Sponsor Name:Bayer AG
    Full Title: Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaba...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10053468 Anticoagulant therapy PT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) LV (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003132-12 Sponsor Protocol Number: s57150 Start Date*: 2015-11-20
    Sponsor Name:UZLeuven
    Full Title: apixaban in end -stage renal disease
    Medical condition: the pharmacokinetics profile of Apixaban allows safe use in patients with end-stage renal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024597-19 Sponsor Protocol Number: CV185-079 Start Date*: 2011-06-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Multiple-Dose Study Apixaban in Pediatric Subjects with an Indwelling Central Venous Catheter Revised Protocol 03, to incorporate Protocol amendments 1, 3 & 4
    Medical condition: Prevention of VTE in pediatric subject with a central venous cathether.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10043628 Thrombosis NOS LLT
    14.1 10047065 - Vascular disorders 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) NL (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003076-14 Sponsor Protocol Number: ANT-007 Start Date*: 2022-05-10
    Sponsor Name:Anthos Therapeutics
    Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in ...
    Medical condition: venous thromboembolism (VTE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-008298-77 Sponsor Protocol Number: CV185-068 Start Date*: 2009-04-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome
    Medical condition: Subjects with a recent acute coronary syndrome (ACS) and at least 2 additional risk factors for recurrent ischemic events.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) NO (Completed) ES (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) DK (Completed) CZ (Prematurely Ended) BE (Completed) HU (Prematurely Ended) DE (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001581-15 Sponsor Protocol Number: CV185-118 Start Date*: 2013-04-25
    Sponsor Name:Bristol-Myers Squibb Company
    Full Title: Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder
    Medical condition: Thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10043566 Thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001601-23 Sponsor Protocol Number: s63950 Start Date*: 2020-06-18
    Sponsor Name:University Hospitals of Leuven
    Full Title: Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long term parenteral nutrition
    Medical condition: theoretically none (PK study), but drug is used for prevention or treatment of VTE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005439-15 Sponsor Protocol Number: CAP Start Date*: Information not available in EudraCT
    Sponsor Name:Akershus University Hospital
    Full Title: Apixaban for treatment of venous thrombosis in patients with cancer.
    Medical condition: Venous thrombosis in patients with cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003852-19 Sponsor Protocol Number: DOAC Start Date*: 2019-03-29
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: An Open Label, Non-Randomised, Phase IV Clinical Trial to Determine the Transfer of Apixaban and Rivaroxaban in Breast Milk Following Oral Administration
    Medical condition: healthy volunteers (Venous Thromboembolism)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003342-25 Sponsor Protocol Number: P170604J Start Date*: 2018-09-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis
    Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076654 Cancer-associated thrombosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) AT (Ongoing) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000055-41 Sponsor Protocol Number: CV185-220 Start Date*: 2013-08-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
    Medical condition: Patients with Non-Valvular Atrial Fibrillation with at least one risk factor for stroke and indicated for oral anticoagulant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001013-32 Sponsor Protocol Number: CV-185-685 Start Date*: 2018-11-08
    Sponsor Name:HOSPITAL CLÍNIC BARCELONA
    Full Title: ANTITHROMBOTIC THERAPY AFTER LEFT ATRIAL APPENDAGE OCCLUSION: DOUBLE ANTIPLATELET THERAPY VS. APIXABAN
    Medical condition: ATRIAL FIBRILLATION IN PATIENTS AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003569-91 Sponsor Protocol Number: NL62896 Start Date*: 2017-12-08
    Sponsor Name:Hagaziekenhuis
    Full Title: The effect of body weight on trough concentrations of DOACs in patients.
    Medical condition: No medical condition will be investigated. This study will only investigate the effect of body weight on through concentrations of direct oral anticoagulants (DOACs)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001388-71 Sponsor Protocol Number: CV185-017 Start Date*: 2005-11-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic ...
    Medical condition: Acute Symptomatic Deep Vein Thrombosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003093-40 Sponsor Protocol Number: FADOI_032016 Start Date*: 2017-03-10
    Sponsor Name:FONDAZIONE FADOI
    Full Title: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study- the CARAVAGGIO study.
    Medical condition: Venous thromboembolism in cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PT (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003674-96 Sponsor Protocol Number: CV185-036 Start Date*: 2007-07-27
    Sponsor Name:Bristol Myers Squibb
    Full Title: A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Fo...
    Medical condition: Total Venous thromboembolism (VTE), defined as the combination of fatal or nonfatal pulmonary embolism, symptomatic deep vein thrombosis (DVT), and asymptomatic proximal DVT.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051055 Deep vein thrombosis LLT
    9.1 10037377 Pulmonary embolism LLT
    9.1 10049918 Deep venous thrombosis proximal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DK (Completed) HU (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001557-26 Sponsor Protocol Number: CV185-048 Start Date*: 2008-04-29
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial ...
    Medical condition: Patients with atrial fibrillation and at least one additional risk factor for stroke who have failed or are unsuitable for vitamin K antagonist therapy.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) SE (Completed) BE (Completed) DE (Completed) FI (Completed) ES (Completed) DK (Completed) CZ (Completed) AT (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001212-29 Sponsor Protocol Number: Prot-0824-2019 Start Date*: 2020-08-26
    Sponsor Name:Aarhus University Hospital, Henrik Birn
    Full Title: Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
    Medical condition: Nephrotic syndrome is defined as severe proteinuria (> 3.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10029167 Nephrotic syndrome with lesion of membranous glomerulonephritis LLT
    20.0 100000004857 10029165 Nephrotic syndrome in diseases classified elsewhere LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 14:17:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA